Alzheimer’s disease development is entering a new phase. With disease-modifying therapies making up a significant share of the 2025 AD pipeline, sponsors are navigating a trial landscape shaped by earlier intervention, biomarker-driven diagnosis, and growing complexity in patient identification and enrollment.
This infographic highlights three shifts influencing next-generation AD trial execution — from the evolving development pipeline to the operational realities of enrolling preclinical and early-stage participants, and the design strategies needed to preserve rigor while reducing burden.
What’s Inside:
Explore key considerations shaping Alzheimer’s trial execution, including:
- Pipeline trends driving continued focus on disease-modifying therapies
- Enrollment challenges tied to identifying preclinical and early-stage participants
- Recruitment pathways across community, primary care, memory clinic, and biomarker-based settings
- Trial design strategies that support rigor while reducing operational burden
